Estrogen Receptor (ER) in Breast Cancer: What the Stain Tells Us, and What It Doesn't

A tumor board pauses over a slide. The invasive ductal carcinoma is unremarkable in most respects, but the ER immunostain reads 3%. Three percent — positive by the letter of the guideline, yet close enough to the cutoff that the room hesitates. Does this patient belong on the endocrine-eligible pathway, or is her tumor behaving, biologically, like an ER-negative cancer? That small number carries real weight, and the conversation it provokes is exactly why ER testing deserves careful attention.

What the test measures

Estrogen receptor is a nuclear hormone receptor. When estrogen binds, the receptor acts as a transcription factor, driving expression of genes that promote proliferation in hormone-responsive breast epithelium. A subset of breast cancers retains this machinery and depends, at least in part, on estrogen signaling for growth. Detecting ER in the tumor tells us whether that dependency may exist — and therefore whether therapies aimed at the estrogen axis have a plausible target to act on.

The assay does not measure receptor function directly. It measures the presence of receptor protein in tumor cell nuclei. That distinction matters when we interpret weak or borderline results.

How it's tested

ER is assessed by immunohistochemistry (IHC) on formalin-fixed, paraffin-embedded (FFPE) tissue. The antibody binds ER protein; a chromogenic detection system renders positive nuclei visible under the microscope. Conceptually simple, but the result is only as trustworthy as the tissue handling that precedes it.

Preanalytic variables can degrade the antigen before a pathologist ever sees the slide. The ASCO/CAP guideline specifies cold ischemia time — the interval between tissue removal and fixation — of under one hour, and fixation in 10% neutral buffered formalin for 6 to 72 hours [1]. Underfixation and overfixation both introduce error, as does prolonged warm ischemia. These aren't bureaucratic details; a falsely low ER result can misroute a patient's entire treatment pathway. The CAP breast protocol reinforces documentation of these parameters as part of standardized reporting [2].

Scoring is deliberately straightforward: the pathologist estimates the percentage of invasive tumor nuclei showing ER staining at any intensity. Any staining counts — faint or strong — provided it is nuclear and unequivocal. A recommended positive control on the same slide confirms the run performed as expected [1].

What each result state means

ER negative (<1%). Fewer than 1% of tumor nuclei stain. The tumor is considered to lack meaningful estrogen receptor expression. Assuming valid controls and adequate preanalytics, endocrine dependency is not expected.

ER-low positive (1–10%). This is the zone that makes tumor boards uneasy. The 2020 guideline formally recognizes 1–10% as positive but flags it as a distinct biologic category, recommending an explicit comment in the report [1]. These tumors are technically ER-positive, yet a growing body of data suggests many of them behave more like ER-negative disease. Calling it "positive" without the accompanying caveat obscures genuine uncertainty about how these tumors will respond.

ER positive (≥10%). Ten percent or more of tumor nuclei stain. This is the population in which endocrine responsiveness is best established and where the evidence for benefit from estrogen-directed therapy is strongest.

What it determines for treatment eligibility

ER positivity functions as a gate. A positive result establishes eligibility for consideration of endocrine therapies — a class that includes selective estrogen receptor modulators (SERMs), aromatase inhibitors, and selective estrogen receptor degraders (SERDs). ER status also contributes, alongside other clinical and pathologic factors, to eligibility for CDK4/6 inhibitors [1].

The point here is narrow and important: ER testing informs whether a drug class is on the table for a given tumor. It does not, on its own, dictate that any individual should receive a particular agent. Sequencing, dosing, and the decision to treat at all belong to the treating oncologist and patient, weighing the full clinical picture. The pathology report opens a door; it does not walk the patient through it.

Caveats and what's evolving

The 1% threshold is a pragmatic line drawn across a biological continuum, and it remains contested. When ASCO/CAP lowered the positivity cutoff, the intent was to avoid denying endocrine therapy to patients who might benefit — an understandable bias toward inclusion. But the accumulating evidence for the 1–10% group is genuinely mixed. Tumors in this range often carry gene expression profiles and clinical behavior closer to ER-negative disease than to strongly ER-positive cancers, and the magnitude of endocrine therapy benefit in this narrow band is far less certain than it is above 10% [1]. This is precisely why the guideline asks pathologists not simply to report "positive," but to append a comment noting the limited and uncertain data on endocrine responsiveness at these levels [1]. That comment isn't hedging for its own sake — it hands the tumor board the context needed to make an informed decision rather than a reflexive one.

Practically, this means the pathologist's report in the 1–10% range does more work than a bare percentage. It should prompt a conversation, not close one. There's also honest debate about reproducibility at the low end: estimating whether staining sits at 1% or below is inherently imprecise, and interobserver variability is real. Preanalytic fidelity matters most here, where a modest antigen loss can flip a result across the clinically meaningful line.

A related development worth understanding is the emergence of HER2-low as a category. HER2-low tumors — those with low-level HER2 expression that would previously have been grouped with HER2-negative disease — are now recognized as therapeutically distinct. Many ER-positive breast cancers also fall into the HER2-low group, and that dual characterization can change which systemic options a tumor board considers for a given patient. ER status doesn't exist in isolation; it's interpreted alongside HER2 and other markers, and the recategorization of HER2 has shifted the surrounding context in which an ER-positive result is read.

The open question that lingers over the 1–10% zone is whether these tumors constitute a coherent group at all, or a heterogeneous mix in which a minority are truly endocrine-responsive and the rest are misclassified by an antibody detecting protein that no longer drives the tumor. Until that question is resolved with prospective outcome data, the honest position for the diagnostic pathologist is to report the number, flag the uncertainty, and resist the temptation to let a single percentage settle a decision it was never designed to make on its own.

References

1. Allison KH, Hammond MEH, Dowsett M, et al. Estrogen and Progesterone Receptor Testing in Breast Cancer: ASCO/CAP Guideline Update. J Clin Oncol / Arch Pathol Lab Med. 2020. doi:10.1200/JCO.19.02309.
2. College of American Pathologists. Protocol for the Examination of Specimens From Patients With Invasive Carcinoma of the Breast. CAP Cancer Protocols (current version).